Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1481)	10/8/1998 10:14:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

David: Sure! I found the 0.42% reduction in those with HbAlc>8% in the 150mg dose group to be a worthwhile reduction. The probability of <0.005 for 105 patients augers well for the current trial. Combining this result with the 12 month weight loss (p<.003)plus the 8% increase in HDL/LDL (p<.001) seems like useful medicine to me. Incidentally, your name reminds me of the time I was in Florence with a tour group looking at Michelangelo's statue of David when a woman asked whether this was all there was in the museum. The guide said "Senora - is this not enough?". Regards Arnie